The biopharma/device merger and acquisitions space is proving extremely lively in 2014, and an early read on the magnitude of risk is essential for effectively triaging deal flow. Join Avalere and industry experts as we discuss two of the most significant questions that companies face when acquiring or in-licensing a drug, biologic or device: will the product navigate the regulatory system, and, if so, will it be reimbursed. Our webinar will discuss ways to organize and weigh these risks. It will allow you to effectively consider and quantify risk, and will give you strategies to manage and mitigate the uncertainties. This information will help you gauge risk and reward, assess commercial implications, and efficiently manage your deal flow.
Key Learning Objectives:
- Learn about typical regulatory and reimbursement risks for potential drug, biologic and device acquisitions and in-licensing opportunities
- Identify ways to quantify these key risks
- Explore ways to mitigate these key risks
Hosted by BioCentury